{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:08:25Z","timestamp":1794917305569,"version":"4.9.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Several clinical risk models have been proposed to predict the outcome of follicular lymphoma (FL). The development of next-generation sequencing technologies has allowed the integration of somatic gene mutations into clinical scores to build genotyped-based risk models, such as the m7\u2013Follicular Lymphoma International Prognostic Index (FLIPI). We explored 4 clinical or clinicogenetic-risk models in patients with symptomatic FL who received frontline immunochemotherapy. Of 191 patients with FL grades 1 to 3a, 109 were successfully genotyped. The treatment consisted of rituximab (R) plus cyclophosphamide, vincristine, and prednisone (R-CVP)\/cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (72.5%) or R-bendamustine (R-B) (27.5%). The proportion of cases classified as high risk for FLIPI, FLIPI-2, PRIMA\u2013prognostic index, or m7-FLIPI were 39.3%, 14%, 30.3%, and 22%, respectively. No case with low-intermediate FLIPI was upgraded in the m7-FLIPI, but 18 of the 42 high-risk patients with FLIPI were downgraded to low-risk m7-FLIPI. The sensitivity and specificity for the prediction of POD24 were highest for FLIPI. The discrimination between progression-free survival (PFS) and overall survival (OS) was the best for FLIPI (c-index: 0.644 and 0.727, respectively). When analyzed only in patients treated with R-B, m7-FLIPI showed a higher discrimination between PFS and OS. Thus, the FLIPI remains the clinical risk score with higher discrimination in patients with advanced FL treated with immunochemotherapy; however, the performance of the m7-FLIPI should be further investigated in patients treated with R-B.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007949","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T18:17:09Z","timestamp":1666203429000},"page":"1606-1614","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-7925","authenticated-orcid":false,"given":"Juan Jose","family":"Rodr\u00edguez-Sevilla","sequence":"first","affiliation":[{"name":"1Department of Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain"},{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"},{"name":"3Department of Pathology, IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Bento","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Son Espases Hospital, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Diez-Feij\u00f3o","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain"},{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-2582","authenticated-orcid":false,"given":"Sergio","family":"Pinz\u00f3n","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain"},{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-0759","authenticated-orcid":false,"given":"Joan","family":"Gibert","sequence":"additional","affiliation":[{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"},{"name":"3Department of Pathology, IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lierni","family":"Fern\u00e1ndez-Ibarrondo","sequence":"additional","affiliation":[{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"},{"name":"3Department of Pathology, IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lafuente","sequence":"additional","affiliation":[{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"},{"name":"5Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-9472","authenticated-orcid":false,"given":"Ana","family":"Ferrer","sequence":"additional","affiliation":[{"name":"3Department of Pathology, IMIM, Barcelona, Spain"},{"name":"6Translational Research Group on Hematological Neoplasms, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain"},{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gimeno","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain"},{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-2423","authenticated-orcid":false,"given":"Juan","family":"Sainz","sequence":"additional","affiliation":[{"name":"7Genomic Oncology Area (GENYO), Centre for Genomics and Oncological Research: Pfizer\/University of Granada\/Andalusian Regional Government, PTS Granada, Granada, Spain"},{"name":"8Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA), Complejo Hospitalario Universitario de Granada\/University of Granada, Granada, Spain"},{"name":"9Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Ramos","sequence":"additional","affiliation":[{"name":"10Department of Pathology, Son Espases Hospital, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-0806","authenticated-orcid":false,"given":"Juan F.","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"11Department of Pathology, MD Anderson Cancer Center, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Colomo","sequence":"additional","affiliation":[{"name":"3Department of Pathology, IMIM, Barcelona, Spain"},{"name":"6Translational Research Group on Hematological Neoplasms, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"},{"name":"3Department of Pathology, IMIM, Barcelona, Spain"},{"name":"5Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Son Espases Hospital, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4652-4825","authenticated-orcid":false,"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain"},{"name":"2Group of Applied Clinical Research in Hematology (GRETNHE), Cancer Research Program-IMIM, Barcelona, Spain"},{"name":"5Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"issue":"10","key":"2023042515290783200_bib1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023042515290783200_bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2023042515290783200_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023042515290783200_bib4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2023042515290783200_bib5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"2023042515290783200_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2023042515290783200_bib7","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023042515290783200_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A\u00a0simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2023042515290783200_bib9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9873","key":"2023042515290783200_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"27","key":"2023042515290783200_bib11","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023042515290783200_bib12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023042515290783200_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/bloodadvances.2021005316","article-title":"Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity","volume":"6","author":"Fernandez-Rodr\u0131guez","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2023042515290783200_bib14","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.3324\/haematol.2018.187773","article-title":"Impact of age on genetics and treatment efficacy in follicular lymphoma","volume":"103","author":"Alig","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"2023042515290783200_bib15","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"18","key":"2023042515290783200_bib16","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1182\/bloodadvances.2020002546","article-title":"Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models","volume":"4","author":"Alig","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2023042515290783200_bib17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/bloodadvances.2019032136","article-title":"Impact of age on clinical risk scores in follicular lymphoma","volume":"3","author":"Alig","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2023042515290783200_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2023042515290783200_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2019-130208","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the Gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy","volume":"134","author":"Jurinovic","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2023042515290783200_bib20","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023042515290783200_bib21","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ajh.25973","article-title":"Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","volume":"95","author":"Mir","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"2023042515290783200_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A\u00a0gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023042515290783200_bib23","doi-asserted-by":"crossref","first-page":"705010","DOI":"10.3389\/fonc.2021.705010","article-title":"Personally tailored survival prediction of patients with follicular lymphoma using machine learning transcriptome-based models","volume":"11","author":"Mosquera Orgueira","year":"2022","journal-title":"Front Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/8\/1606\/2045733\/blooda_adv-2022-007949-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/8\/1606\/2045733\/blooda_adv-2022-007949-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:56:19Z","timestamp":1682438179000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/8\/1606\/486841\/Evaluation-of-4-prognostic-indices-in-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,4,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007949","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}